BACKGROUND AND PURPOSE: Transglutaminase 2 (TGase 2) expression is increased in inflammatory diseases, and TGase 2 inhibitors block these increases. We examined whether the R2 peptide inhibited the expression of TGase 2 in a mouse model of inflammatory allergic asthma. EXPERIMENTAL APPROACH: C57BL/6 mice were sensitized and challenged by ovalbumin (OVA) to induce asthma. OVA-specific serum IgE and leukotrienes (LTs) levels were measured by enzyme-linked immunosorbent assay. Recruitment of inflammatory cells into bronchoalveolar lavage (BAL) fluid or lung tissues and goblet cell hyperplasia were assessed histologically. Airway hyperresponsiveness was determined in a barometric plethysmographic chamber. Expression of TGase 2, eosinophil major basic protein (EMBP), the adhesion molecule vascular cell adhesion molecule-1, Muc5ac and phospholipase A(2) (PLA(2) ) protein were determined by Western blot. Expression of mRNAs of Muc5ac, cytokines, matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) were measured by reverse transcriptase-polymerase chain reaction and nuclear factor-κB (NF-κB) by electrophoretic mobility shift assay. KEY RESULTS: R2 peptide reduced OVA-specific IgE levels; the number of total inflammatory cells, macrophages, neutrophils, lymphocytes and eosinophils in BAL fluid and the number of goblet cells. Airway hyperresponsiveness, TGase 2 and EMBP levels, mRNA levels of interleukin (IL)-4, IL-5, IL-6, IL-8, IL-13, RANTES, tumour necrosis factor-α, and MMP2/9, Muc5ac, NF-κB activity, PLA(2) activity and expressions, and LT levels in BAL cells and lung tissues were all reduced by R2 peptide. R2 peptide also restored expression of TIMP1/2. CONCLUSION AND IMPLICATIONS: R2 peptide reduced allergic responses by regulating NF-κB/TGase 2 activity in a mouse model of allergic asthma. This peptide may be useful in the treatment of allergic asthma.
BACKGROUND AND PURPOSE:Transglutaminase 2 (TGase 2) expression is increased in inflammatory diseases, and TGase 2 inhibitors block these increases. We examined whether the R2 peptide inhibited the expression of TGase 2 in a mouse model of inflammatory allergic asthma. EXPERIMENTAL APPROACH: C57BL/6 mice were sensitized and challenged by ovalbumin (OVA) to induce asthma. OVA-specific serum IgE and leukotrienes (LTs) levels were measured by enzyme-linked immunosorbent assay. Recruitment of inflammatory cells into bronchoalveolar lavage (BAL) fluid or lung tissues and goblet cell hyperplasia were assessed histologically. Airway hyperresponsiveness was determined in a barometric plethysmographic chamber. Expression of TGase 2, eosinophil major basic protein (EMBP), the adhesion molecule vascular cell adhesion molecule-1, Muc5ac and phospholipase A(2) (PLA(2) ) protein were determined by Western blot. Expression of mRNAs of Muc5ac, cytokines, matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) were measured by reverse transcriptase-polymerase chain reaction and nuclear factor-κB (NF-κB) by electrophoretic mobility shift assay. KEY RESULTS: R2 peptide reduced OVA-specific IgE levels; the number of total inflammatory cells, macrophages, neutrophils, lymphocytes and eosinophils in BAL fluid and the number of goblet cells. Airway hyperresponsiveness, TGase 2 and EMBP levels, mRNA levels of interleukin (IL)-4, IL-5, IL-6, IL-8, IL-13, RANTES, tumour necrosis factor-α, and MMP2/9, Muc5ac, NF-κB activity, PLA(2) activity and expressions, and LT levels in BAL cells and lung tissues were all reduced by R2 peptide. R2 peptide also restored expression of TIMP1/2. CONCLUSION AND IMPLICATIONS: R2 peptide reduced allergic responses by regulating NF-κB/TGase 2 activity in a mouse model of allergic asthma. This peptide may be useful in the treatment of allergic asthma.
Authors: D Sánchez; L Tucková; P Sebo; M Michalak; A Whelan; I Sterzl; L Jelínková; E Havrdová; M Imramovská; Z Benes; S Krupicková; H Tlaskalová-Hogenová Journal: J Autoimmun Date: 2000-12 Impact factor: 7.094
Authors: C L Ordoñez; R Khashayar; H H Wong; R Ferrando; R Wu; D M Hyde; J A Hotchkiss; Y Zhang; A Novikov; G Dolganov; J V Fahy Journal: Am J Respir Crit Care Med Date: 2001-02 Impact factor: 21.405
Authors: Eunsung Junn; Ruben D Ronchetti; Martha M Quezado; Soo-Youl Kim; M Maral Mouradian Journal: Proc Natl Acad Sci U S A Date: 2003-02-07 Impact factor: 11.205
Authors: Eleanor S Roberts; Michelle A Zandonatti; Debbie D Watry; Lisa J Madden; Steven J Henriksen; Michael A Taffe; Howard S Fox Journal: Am J Pathol Date: 2003-06 Impact factor: 4.307
Authors: Zeneng Wang; Joseph A DiDonato; Jennifer Buffa; Suzy A Comhair; Mark A Aronica; Raed A Dweik; Nancy A Lee; James J Lee; Mary Jane Thomassen; Mani Kavuru; Serpil C Erzurum; Stanley L Hazen Journal: J Biol Chem Date: 2016-09-01 Impact factor: 5.157
Authors: Teal S Hallstrand; William A Altemeier; Moira L Aitken; William R Henderson Journal: Immunol Allergy Clin North Am Date: 2013-03-29 Impact factor: 3.479
Authors: Frank Soveg; Hiam Abdala-Valencia; Jackson Campbell; Luisa Morales-Nebreda; Gökhan M Mutlu; Joan M Cook-Mills Journal: Am J Physiol Lung Cell Mol Physiol Date: 2015-07-24 Impact factor: 5.464
Authors: Teal S Hallstrand; Ying Lai; William R Henderson; William A Altemeier; Michael H Gelb Journal: Pulm Pharmacol Ther Date: 2012-12 Impact factor: 3.410
Authors: Teal S Hallstrand; Ying Lai; William A Altemeier; Cara L Appel; Brian Johnson; Charles W Frevert; Kelly L Hudkins; James G Bollinger; Prescott G Woodruff; Dallas M Hyde; William R Henderson; Michael H Gelb Journal: Am J Respir Crit Care Med Date: 2013-07-01 Impact factor: 21.405